Literature DB >> 22983903

HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.

Byung-Kwon Choi1, Xiumei Cai, Bin Yuan, Zhao Huang, Xuejun Fan, Hui Deng, Ningyan Zhang, Zhiqiang An.   

Abstract

Dimerization among the EGFR family of tyrosine kinase receptors leads to allosteric activation of the kinase domains of the partners. Unlike other members in the family, the kinase domain of HER3 lacks key amino acid residues for catalytic activity. As a result, HER3 is suggested to serve as an allosteric activator of other EGFR family members which include EGFR, HER2 and HER4. To study the role of intracellular domains in HER3 dimerization and activation of downstream signaling pathways, we constructed HER3/HER2 chimeric receptors by replacing the HER3 kinase domain (HER3-2-3) or both the kinase domain and the C-terminal tail (HER3-2-2) with the HER2 counterparts and expressed the chimeric receptors in Chinese hamster ovary (CHO) cells. While over expression of the intact human HER3 transformed CHO cells with oncogenic properties such as AKT/ERK activation and increased proliferation and migration, CHO cells expressing the HER3-2-3 chimeric receptor showed significantly reduced HER3/HER2 dimerization and decreased phosphorylation of both AKT and ERK1/2 in the presence of neuregulin-1 (NRG-1). In contrast, CHO cells expressing the HER3-2-2 chimeric receptor resulted in a total loss of downstream AKT activation in response to NRG-1, but maintained partial activation of ERK1/2. The results demonstrate that the intracellular domains play a crucial role in HER3's function as an allosteric activator and its role in downstream signaling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22983903      PMCID: PMC4875347          DOI: 10.1007/s13238-012-2065-y

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  22 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Authors:  Birgit Schoeberl; Emily A Pace; Jonathan B Fitzgerald; Brian D Harms; Lihui Xu; Lin Nie; Bryan Linggi; Ashish Kalra; Violette Paragas; Raghida Bukhalid; Viara Grantcharova; Neeraj Kohli; Kip A West; Magdalena Leszczyniecka; Michael J Feldhaus; Arthur J Kudla; Ulrik B Nielsen
Journal:  Sci Signal       Date:  2009-06-30       Impact factor: 8.192

4.  Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein.

Authors:  S L Sierke; K Cheng; H H Kim; J G Koland
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

5.  Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling.

Authors:  Alexander W Krug; Claudia Schuster; Birgit Gassner; Ruth Freudinger; Sigrid Mildenberger; Jakob Troppmair; Michael Gekle
Journal:  J Biol Chem       Date:  2002-09-19       Impact factor: 5.157

6.  Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.

Authors:  Murli Narayan; Jason A Wilken; Lyndsay N Harris; Andre T Baron; Kimberly D Kimbler; Nita J Maihle
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 7.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Authors:  José Baselga; Sandra M Swain
Journal:  Nat Rev Cancer       Date:  2009-06-18       Impact factor: 60.716

8.  ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.

Authors:  Mitchell B Berger; Jeannine M Mendrola; Mark A Lemmon
Journal:  FEBS Lett       Date:  2004-07-02       Impact factor: 4.124

Review 9.  A pan-HER approach for cancer therapy: background, current status and future development.

Authors:  Zhongdong Huang; Cathleen Brdlik; Pei Jin; H Michael Shepard
Journal:  Expert Opin Biol Ther       Date:  2009-01       Impact factor: 4.388

10.  Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.

Authors:  S D Chan; D M Antoniucci; K S Fok; M L Alajoki; R N Harkins; S A Thompson; H G Wada
Journal:  J Biol Chem       Date:  1995-09-22       Impact factor: 5.157

View more
  11 in total

1.  Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.

Authors:  Subhasis Das; Gautam Sondarva; Navin Viswakarma; Rakesh Sathish Nair; Clodia Osipo; Guri Tzivion; Basabi Rana; Ajay Rana
Journal:  J Biol Chem       Date:  2015-07-07       Impact factor: 5.157

2.  LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions.

Authors:  Peng Zhao; Yuanzhong Xu; Lu-Lin Jiang; Xuejun Fan; Zhiqiang Ku; Leike Li; Xiaoye Liu; Mi Deng; Hisashi Arase; Jay-Jiguang Zhu; Timothy Y Huang; Yingjun Zhao; Chengcheng Zhang; Huaxi Xu; Qingchun Tong; Ningyan Zhang; Zhiqiang An
Journal:  Mol Neurodegener       Date:  2022-06-18       Impact factor: 18.879

3.  Dissociated presenilin-1 and TACE processing of ErbB4 in lung alveolar type II cell differentiation.

Authors:  Najla Fiaturi; Anika Ritzkat; Christiane E L Dammann; John J Castellot; Heber C Nielsen
Journal:  Biochim Biophys Acta       Date:  2014-01-24

Review 4.  Regulation of ERBB3/HER3 signaling in cancer.

Authors:  Kalpana Mujoo; Byung-Kwon Choi; Zhao Huang; Ningyan Zhang; Zhiqiang An
Journal:  Oncotarget       Date:  2014-11-15

5.  HER3 and LINC00052 interplay promotes tumor growth in breast cancer.

Authors:  Ahmad Salameh; Xuejun Fan; Byung-Kwon Choi; Shu Zhang; Ningyan Zhang; Zhiqiang An
Journal:  Oncotarget       Date:  2017-01-24

6.  Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer.

Authors:  Shu Zhang; Seema Mukherjee; Xuejun Fan; Ahmad Salameh; Kalpana Mujoo; Zhao Huang; Leike Li; Georgina To'a Salazar; Ningyan Zhang; Zhiqiang An
Journal:  Oncotarget       Date:  2016-10-04

7.  HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.

Authors:  Kara S Meister; Neal R Godse; Nayel I Khan; Matthew L Hedberg; Carolyn Kemp; Sucheta Kulkarni; Diego Alvarado; Theresa LaVallee; Seungwon Kim; Jennifer R Grandis; Umamaheswar Duvvuri
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

Review 8.  Circular RNA in Lung Cancer Research: Biogenesis, Functions, and Roles.

Authors:  Congcong Zhang; Lifang Ma; Yongjie Niu; Zhixian Wang; Xin Xu; Yan Li; Yongchun Yu
Journal:  Int J Biol Sci       Date:  2020-01-16       Impact factor: 6.580

9.  A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo.

Authors:  Mengjun Shu; Hongbin Yan; Chuanying Xu; Yan Wu; Zhaohua Chi; Weihong Nian; Zhuzi He; Jing Xiao; Hongli Wei; Qing Zhou; Joe X Zhou
Journal:  Sci Rep       Date:  2020-02-19       Impact factor: 4.379

10.  Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.

Authors:  Mohammed Akli Ayoub; Heng B See; Ruth M Seeber; Stephen P Armstrong; Kevin D G Pfleger
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.